Ublituximab is a medicine used to treat multiple sclerosis (MS). It's given as an infusion into a vein, usually twice a year after the first doses. It works by removing a type of immune cell, called B cells, that helps attack the brain and spinal cord.
Every report comes from a Lived member, sent anonymously.
Have you tried Briumvi (Ublituximab) for MS (Multiple Sclerosis)?
Briumvi is the brand name for ublituximab (its full US name is ublituximab-xiiy), a prescription medicine given by infusion to treat relapsing forms of multiple sclerosis (MS) in adults. MS is a disease in which the immune system damages myelin, the protective coating around nerves in the brain and spinal cord. Depending on which nerves are affected, this can cause problems with vision, strength, sensation, balance, thinking and bladder control. The approval covers three relapsing forms. Clinically isolated syndrome is a first episode of MS-like symptoms that may or may not develop into MS. Relapsing-remitting MS, the most common type, involves flare-ups of new or worsening symptoms (relapses) followed by periods of recovery. Active secondary progressive MS is a later phase in which symptoms gradually worsen while disease activity continues. Ublituximab is not approved for primary progressive MS or for children. It is a disease-modifying therapy: the aim is to prevent new relapses and new nerve damage over time, not to relieve symptoms someone already has.
Ublituximab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is CD20, a marker on the surface of B cells, a type of white blood cell. Once the antibody attaches, the immune system destroys those cells, and B-cell numbers in the blood drop within a day of the first infusion and stay low between doses. B cells are thought to help drive the immune attack on myelin, and removing them calms the inflammation behind relapses. Researchers do not know exactly how this produces the benefit in MS. Because B cells also help fight infections and respond to vaccines, the same effect explains several of the medicine's main risks. After treatment stops, B cells return slowly: in the trials, it took a median of about 16 months.
Ublituximab is given as an infusion into a vein (intravenous, or IV) at an infusion center or clinic, by staff equipped to manage reactions. The first dose is 150 mg, infused slowly over about four hours. A 450 mg dose follows two weeks later and usually takes about an hour. After that, a 450 mg infusion is given every 24 weeks (roughly every six months), counted from the first infusion. An infusion can take longer if it is slowed or paused because of a reaction. Before every infusion, people receive a corticosteroid (usually methylprednisolone) and an antihistamine such as diphenhydramine, sometimes with acetaminophen, to make infusion reactions less likely and milder. After each of the first two infusions, people stay for at least an hour of observation. Before the first dose, the care team tests for hepatitis B, measures antibody (immunoglobulin) levels, checks liver blood tests and brings vaccines up to date. If you have an active infection on an infusion day, the dose is postponed until it clears. A missed infusion is given as soon as possible rather than at the next scheduled date, and the schedule then restarts from that dose; infusions are always at least five months apart.
Infusion reactions are the most common side effect. In the main trials, 43% of people had one with the first infusion, falling to 10% with the second and 8% with the third. Typical symptoms are fever, chills, headache and flu-like aches; a fast heartbeat, nausea, throat irritation or skin redness can also occur. Most are handled by slowing or pausing the infusion. Serious reactions affected 0.6% of people, and a severe allergic reaction (anaphylaxis) is possible, which is why staff watch closely. Reactions can begin up to 24 hours after an infusion, so contact the care team right away if these symptoms start after you get home. Infections are the other main side effect. Colds, sinus and throat infections were the most common, followed by urinary tract infections, chest infections such as bronchitis, and herpes virus infections. Serious infections were more frequent than with the comparison medicine in the trials (5% versus 3%), and three people taking ublituximab died of infections. Tell the care team about fever, chills, a cough that won't go away or pain when urinating, both during treatment and after the last infusion. Some people also notice pain in the arms or legs, trouble sleeping or tiredness.
Ublituximab is not given to people with active hepatitis B or to anyone who has had a life-threatening reaction to it. In people who carry the hepatitis B virus, B-cell-depleting antibodies can reawaken it, and this has caused liver failure and death; that is why everyone is tested first, and people with signs of past infection are managed with a liver specialist. Progressive multifocal leukoencephalopathy (PML) is a rare brain infection caused by the JC virus that usually leads to death or severe disability, and it has occurred with ublituximab. Its symptoms build over days to weeks: weakness on one side of the body, clumsiness, vision changes, or confusion and changes in memory or personality. Because these can look like an MS relapse, contact the care team promptly about any new or worsening symptoms of this kind. Liver injury has been reported weeks to months after a dose. Contact the care team promptly about unusual tiredness, loss of appetite, nausea or vomiting, pain in the upper right belly, dark urine, or yellowing of the skin or eyes. Live vaccines are not recommended during treatment or until B cells recover, so any that are needed should be given at least four weeks before starting. Other vaccines are best given at least two weeks before starting, because ublituximab may weaken the response to them. Combining it with other medicines that suppress the immune system, including high-dose steroids, raises infection risk, and the timing of a switch from another MS treatment is planned with that in mind. Antibody levels can fall over time and are checked during treatment. Ublituximab may harm a developing baby and can lower B cells in a newborn exposed before birth. People who could become pregnant should use effective birth control during treatment and for six months after the last dose, and tell the care team about pregnancy plans. Whether it passes into breast milk is not known.
In two trials lasting two years, involving about 1,100 adults with relapsing MS, people taking ublituximab had roughly half as many relapses per year as those taking teriflunomide, a daily MS pill (reductions of 59% and 49%). They also had far fewer new or active areas of inflammation on MRI scans. The trials did not show a clear difference between the two medicines in how many people's disability worsened over those two years, and individual results vary. Treatment itself takes only a few days a year. The first two visits are the longest; after that, a maintenance infusion lasts about an hour plus time for the pre-medicines, twice a year. Reactions, when they happen, are most likely during or in the day after the first infusion. Between infusions, ordinary MS care continues, with neurology visits, periodic MRI scans and blood tests such as antibody levels. Ublituximab is meant as long-term treatment. If it is stopped, B cells take many months to recover, so infection and vaccine precautions carry on for a while after the last dose, and a plan for what comes next matters.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Briumvi (Ublituximab), what you've noticed, or ask the community a question.